TheraNym Biologics Expands CMO Capacity with MSD, Commits $150-$175 Million to New Facility
Aurobindo Pharma Ltd.'s subsidiary, TheraNym Biologics Private Limited, has announced the execution of an additional product schedule with Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD). This agreement significantly expands TheraNym's existing contract manufacturing organization (CMO) relationship with MSD, initially established in May 2024.The newly signed product schedule facilitates the construction of a greenfield project, designated as 'Unit 2.' This facility is set to become a large-scale mammalian Drug Substance manufacturing facility, significantly bolstering TheraNym's capacity in the biologics sector.
Under the terms of the expansion, TheraNym Biologics will undertake the development and commissioning of the Unit 2 facility. The planned infrastructure will include the installation of mammalian cell culture bioreactors, boasting an aggregate capacity of 60 KL (60,000 litres). The facility will also incorporate requisite downstream purification infrastructure necessary for producing Drug Substance.
The ambitious expansion requires a substantial investment. TheraNym plans to invest around USD 150 to 175 million to establish the manufacturing facility. This investment is directed toward building the full capacity of mammalian cell culture bioreactors and the necessary purification systems.
The agreement outlines a clear operational structure where TheraNym Biologics will be responsible for building the manufacturing facility, manufacturing the products, and subsequently supplying the finished goods to MSD, expanding the CMO relationship for biologicals.
The key details of the facility expansion are summarized below:
| Feature | Detail |
|---|---|
| Partner | Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) |
| Agreement Type | Additional Product Schedule / CMO Expansion |
| Project Name | Unit 2 (Greenfield Facility) |
| Facility Type | Large-scale mammalian Drug Substance manufacturing |
| Bioreactor Capacity | 60 KL (60,000 litres) |
| Investment Outlay | USD 150 to 175 million |
| Strategic Goal | Further expansion of CMO operations for biologics |
Stock Price Movement
Aurobindo Pharma Ltd shares settled at ₹1375.50 today, finishing up a strong 2.68% for the day. Throughout the trading session, the stock saw considerable movement, tracking between a low of ₹1346.20 and a high of ₹1379.00.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.